ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1025

Mapping The Health Assessment Questionnaire On a Preference Based Utility Measure In a Large Canadian Rheumatoid Arthritis Cohort: Results From The Ontario Best Practices Research Initiative

Mark Tatangelo1, George A. Tomlinson2 and Claire Bombardier3, 1Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada, 2Dept of Medicine/Rheumatology, Toronto General Hospital, Toronto, ON, Canada, 3Rheumatology, University of Toronto, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Decision analysis and economics

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose: mANMClinical trials are limited in demonstrating the cost effectiveness of biologic therapies, as these studies often do not collect measures required for economic analysis.  Thus we sought to provide a validated algorithm, allowing utility scores to be estimated using mapping (also known as “cross-walking”) of the Health Assessment Questionnaire Disease Index (HAQ-DI) onto a standardized utility measure (EQ-5D). 

Methods: We studied 5971 patient visits for 1911 patients included in the Ontario Best Practices Research Initiative, a clinical registry of RA patients followed in routine care (2008-2013). Data were collected every 6 months and include patient demographics, socioeconomic status, clinical variables, disease activity measures, and HAQ-DI and EQ-5D. Each patient’s EQ-5D score was converted to a utility value using a Canadian tariff. EQ-5D utility values were then predicted from HAQ-DI scores using a linear random effects model. HAQ-DI scores were entered as predictors in the model. Random effects for each patient were fitted for intercepts and slopes for the effect of HAQ-DI. Linearity was assessed by fitting non-parametric estimate calculated by mean EQ-5D grouped by HAQ scores.

Results: The estimated fixed effect change in EQ-5D for each point of the HAQ-DI scores is -0.15 (SE=0.0027, P<0.001), with a RMSE= 0.099, and R²=0.68. Examination of the residual plots suggested mild departures from normality with slightly smaller variance for large EQ-5D values (Figure 1). EQ-5D health utility scores showed a ceiling effect, with 1621 observations achieving a utility value of 1 (perfect health).

Figure 1.

Description: Description: Macintosh HD:Users:marktatangelo:Desktop:figure for acr.jpeg

Conclusion: Preference based utility values like the EQ-5D can be estimated using measures such as the HAQ. These results are important because they allow for accurate prediction of average utility values from functional measures included in current clinical trials. This model will allow for economic analyses of the benefit of biologic rheumatic drugs in Quality Adjusted Life Years that are meaningful to payers. Future analysis will use each HAQ item to predict EQ-5D utility score, and external validation of the algorithm.


Disclosure:

M. Tatangelo,
None;

G. A. Tomlinson,
None;

C. Bombardier,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mapping-the-health-assessment-questionnaire-on-a-preference-based-utility-measure-in-a-large-canadian-rheumatoid-arthritis-cohort-results-from-the-ontario-best-practices-research-initiative/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology